Catalyst
Slingshot members are tracking this event:
LUXTURNA (voretigene neparvovec) gene therapy for the treatment of patients with vision loss due to Leber congenital amaurosis PDUFA date set for Jan. 12, 2018.
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ONCE | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 19, 2017
Occurred Source:
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm589467.htm
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Luxturna, Voretigene Neparvovec, First Gene Therapy, Vision Loss, Leber Congenital Amaurosis, Retinitis Pigmentosa
